Yelena Y. Janjigian, MD, discusses results from the primary progression-free survival and interim overall survival analyses of the phase 3 KEYNOTE-811 trial in patients with HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma, and contextualizes these findings with previously reported data from this trial.